Background Psoriasis is a chronic T-cell-mediated skin disease with marked social and economic burdens. Current treatments are unsatisfactory, with unpredictable remission times and incompletely understood modes of action. Recent advances in our understanding of the pathogenesis of psoriasis have identified the imbalance between CD4 + T effector cells, particularly the T helper (Th)17 subset, and
Psoriasis is a chronic relapsing skin disease that affects 2-4% of the population in Western countries. 1 Although not contagious, psoriasis greatly impacts on patients' quality of life, and has been linked with social stigmatization, discomfort and psychological distress. 2 Despite the availability of many treatments, responses remain unsatisfactory, and the frequent relapses, together with absence of long-term control, make psoriasis a challenging condition. This therapeutic inadequacy reflects the need for a more complete understanding of the cellular and molecular determinants of psoriasis. An important advance has been recognition that the disease is mediated by T cells, and that different CD4 + T helper (Th) cell or regulatory T (Treg) subsets can drive or control the pathogenic responses. For many years, psoriasis was classified as a Th1-mediated skin disease. 3 However, the recent description of abundant Th17 cells in psoriasis lesions, 4 and the evidence of impaired Treg function, 5 have led to a new model in which the disease is caused by an imbalance between inflammatory effector T (Teff) cells, represented by Th17 and to a lesser extent Th1 subsets, and Tregs. 5 Although skewing a Th17 bias back towards Tregs is emerging as a rational therapeutic goal in psoriasis, it is not known how effectively conventional and more recent treatments correct this balance, and whether any such restoration correlates with clinical improvement. Nonselective treatments such as ciclosporin 6 inhibit both Teffs and Tregs, leading to rebound of psoriasis on stopping therapy. Narrowband ultraviolet B (NB-UVB) is a popular and effective tool, yet the molecular mechanisms underlying its efficacy are incompletely understood. 7 More recently, anti-tumour necrosis factor (TNF)-a reagents such as adalimumab have emerged as valuable biological agents with significant antiinflammatory effects, although with introduction to regular clinical use, they are associated with side-effects, loss of efficacy and paradoxical cases of psoriasis. 8 Dovobetâ (LEO Pharma, Princes Risborough, U.K.), containing betamethasone and the synthetic vitamin D derivative calcipotriol, is widely used in clinical practice owing to its complementary antiproliferative and anti-inflammatory mechanisms. 9 Vitamin D3
analogues were also found to have beneficial effects in murine models of autoimmune, allergic and inflammatory diseases. 10 Overall, we suggest that better understanding of the mechanisms of success of these treatments can lead to innovation of new, more targeted therapeutic strategies with fewer sideeffects.
In this study, we quantified the effects of NB-UVB, adalimumab and Dovobet on circulating and skin T cells, with particular interest in the critical balance between Th17 and Treg cells, and correlated these changes to clinical response measured by Psoriasis Area and Severity Index (PASI) score. In particular, we wanted to test whether the most effective treatments would skew this balance in favour of Tregs, which are predicted to be important for immune tolerance and prevention of autoimmunity.
Patients and methods

Patients
This study was approved by the North of Scotland Research Ethics Committee and the Medicines and Healthcare Products Regulatory Agency according to the Declaration of Helsinki protocols. All participants signed written informed consent. Thirty-four patients (23 male and 11 female; mean age 50 AE 14Á5) were recruited from Aberdeen Royal Infirmary, Scotland, U.K., with moderate-to-severe psoriasis untreated with topical therapy for 2 weeks or with systemic therapy for 4 weeks. Blood samples and 6-mm punch biopsies were taken from lesional skin at baseline and 6 weeks after treatment with each of NB-UVB (n = 15), adalimumab (n = 11) and Dovobet â (n = 8). Nonlesional 6-mm punches were taken from one group of patients (n = 8) at baseline. The number of patients studied was limited by the restricted inclusion and exclusion criteria, as we were looking for treatment-naive patients to avoid bias in the results. Lesional biopsies were taken from the centre of plaques, and nonlesional samples were taken from the adjacent psoriasisfree skin. Post-treatment samples were collected from cleared psoriatic skin at the same site as pretreatment samples. We chose 6 weeks for post-treatment samples as data from previous similar experiments showed significant immune response to treatment as early as 4-6 weeks.
Patients with psoriasis for whom the decision to treat with NB-UVB was made were exposed to known amounts of NB-UVB three times weekly according to a standard escalating protocol based on minimal erythemal dose. This is defined as the dose that caused just perceptible erythema 24 h after irradiation. Standard dose ranges were between 0Á55 and 3Á13 J cm À2 . Whole-body UVB was given in a Waldmann 7001 cabinet (Waldmann Lichttechnik GmbH, VillingenSchwenningen, Germany), incorporating 24 100-W Philips TL-01 fluorescent lamps (311-313 nm). Adalimumab is a preloaded pen device that automatically injects the drug by subcutaneous infusion. Injection was done by the patient at home after initial illustration and training by the doctor or biological nurse. The dose was 80 mg subcutaneously at week 0, then 40 mg at week 1 and then every other week thereafter. Betamethasone-calcipotriol (Dovobet) is prescribed as a twice-daily dose for 6 weeks to the affected areas. The selection of patients to the treatment arm was not part of the study and was dictated solely by the clinical need. Control samples were provided by psoriasis-free patients who attended the dermatology clinic for excision of naevi.
Samples
Skin samples were physically disaggregated ex vivo for 1 min using 50-lmol L À1 medicons in the Medimachine (BD Biosciences, San Jose, CA, U.S.A.), allowing for collection of viable lymphocytes. 11 The cell suspension was then used for culture or flow cytometry. 
Statistical analysis
Statistical analyses were carried out using Prism GraphPad 5 for windows, version 5.02, 2008 (GraphPad Software, La Jolla, CA, U.S.A.). A two-tailed paired t-test was used to compare proportions of cells in lesional vs. nonlesional skin, and blood of patients. The Mann-Whitney U-test was used to compare the proportions of cells between blood and skin of patients and healthy controls.
The changes in proportions of T-cell subsets with treatment were correlated to changes in PASI score using Spearman correlation. The level of significance was taken as P ≤ 0Á05.
Results
Clinical response
To study the clinical and immunological effects of the three different therapies, 34 patients with moderate-to-severe psoriasis were recruited and received 6-week treatment regimens of NB-UVB (n = 15), adalimumab (n = 11) or Dovobet (n = 8). All patients responded clinically to treatment; the mean AE SD PASI scores for each treatment group decreased from 5Á7 AE 4Á3 to 1Á5 AE 1Á2, 16Á0 AE 6Á1 to 5Á6 AE 5 and 5Á0 AE 5 to 1Á7 AE 8, respectively.
The skin and blood of patients with psoriasis contain significantly higher proportions of T helper 17 cells and lower proportions of regulatory T cells compared with healthy controls
The proportions of CD4 + Th cells with Th1, Th2, Th17 and Treg phenotypes were compared in lesional and nonlesional skin, and in blood, of patients with psoriasis at enrolment to the study. In line with reports describing the phenotypes of these subsets, and our own previous studies, 4 we used the 16, 17 and IL-23R is expressed only on activated T cells. 18 RORcT is the transcription factor for Th17 cells, 19 and is also expressed by dermal cd T cells. 15 We did not rely on IL-17A expression to identify the Th17-cell population, because IL-17A can be produced by other cells, including cd T cells, CD8 + memory T cells, eosinophils, neutrophils, monocytes and mast cells, contributing to the common pole of IL-17 in psoriasis. [20] [21] [22] [23] Due to this complex origin and phenotyping of Th17 cells, we chose to combine the characteristic chemokines (CCR4 + CCR6 + ), with IL-23R for purification and identification of the Th17-cell population.
Examples of representative flow cytometric data from the blood and skin of patients and healthy controls are illustrated in Figures S5 and S6 (see Supporting Information), and the results are summarized in Figure 1 . The most striking findings were that patients' lesional skin and blood contained both significantly higher proportions of Th17 cells than respective samples from healthy controls (P < 0Á001 and P = 0Á004, respectively) and lower proportions of Tregs (P < 0Á001 and P = 0Á001, respectively). Treg proportions were also significantly lower in patients' nonlesional skin than in healthy donors' skin (P = 0Á007). The highest proportions of Th17 cells were found in lesional skin, and they were also significantly higher than in patients' nonlesional skin (P < 0Á001). Although Th1 cell numbers were generally higher in blood and skin samples from patients than from healthy controls, these increases were not significant, and there were also no differences in the proportions of Th2 cells in samples between the groups. Taken together, these findings support the view that an imbalance between Th17 and Treg cells contributes to psoriasis pathogenesis.
Narrowband ultraviolet B therapy significantly increased the percentages of circulating and skin regulatory T cells
The most marked effect of NB-UVB on the CD4 + subsets of patients was shown on Tregs. Examples of flow cytometric analyses are illustrated in Figure S7 (a-c) (see Supporting Information). A summary of the effects of NB-UVB on various T-cell subsets is shown in Figure 2 . In the 15 tested samples, mean circulating and skin Treg percentages were significantly increased from 2Á96 AE 0Á6 to 8Á92 AE 1Á28 (P < 0Á001) and from 1Á47 AE 0Á8 to 13Á6 AE 2Á53 (P < 0Á001), respectively, after treatment. Th1 cells were significantly reduced, from 4Á3 AE 0Á9 to 1Á2 AE 0Á6 (P = 0Á007) in the blood and from 6Á0 AE 0Á9 to 1Á5 AE 0Á5 (P = 0Á02) in the skin, while Th2 cells were significantly increased from 0Á6 AE 0Á4 to 3Á1 AE 2Á1 in the blood (P = 0Á04) and from 2Á7 AE 0Á5 to 4Á7 AE 2Á7 in the skin (P = 0Á01). A reduction in Th17 cells was not statistically significant in either the blood or the skin. Strikingly, the change in skin Tregs, but not in the other subsets, was positively correlated to clinical improvement assessed by change in PASI score ( Fig. S7d ; see Supporting Information).
Adalimumab therapy significantly reduced T helper 17 proportions without significant effect on regulatory T cells
Patients treated with adalimumab for 6 weeks exhibited a different pattern of shifts in the proportions of CD4 + T-cell subsets from those seen after NB-UVB treatment, with the main effects seen on Th17 cells. Examples of flow cytometric analyses are illustrated in Figure S8 (a-c) (see Supporting Information) and a summary is displayed in Figure 3 . The greatest effect of adalimumab was on the percentages of Th17 cells, which were significantly decreased from 7Á1 AE 0Á4 to 2Á7 AE 0Á1 in the blood (P = 0Á05) and from 21Á7 AE 11Á6 to 9Á5 AE 3Á8 in the skin (P = 0Á005). The proportions of Th1 and Th2 cells showed small nonsignificant increases, in both the blood and the skin, and there was also no statistically significant effect of adalimumab on Tregs, with opposing trends for small decreases in blood but small increases in skin. The fall in skin Th17 numbers, but none of the other changes, was related to clinical improvement, with change in skin Th17 cells significantly correlated to change in PASI. (Fig. S8d) .
Treatment with Dovobet ointment significantly affects T helper 1, 2 and 17 cells and regulatory T cells
Dovobet is a combination of betamethasone dipropionate and active vitamin D (calcipotriol), and has a well-established therapeutic role in psoriasis. We showed highly significant, reciprocal systemic effects of Dovobet on Th17 and Treg cells after treatment for 6 weeks. Examples of flow cytometric analyses are illustrated in Figure S9 (a-c) (see Supporting Information) and are summarized in Figure 4 . Dovobet significantly increased the percentages of Tregs in the circulation (from 3Á3 AE 0Á6 to 7Á3 AE 0Á9, P = 0Á005) and in the skin (from 1Á9 AE 1Á4 to 8Á7 AE 2Á3, P = 0Á01), and decreased those of Th17 cells (from 4Á3 AE 1Á1 to 3Á4 AE 0Á4, P = 0Á003 and from 8Á7 AE 0Á9 to 5Á3 AE 1Á8, P = 0Á01, respectively). The percentages of Th1 cells were also significantly decreased in the skin (P = 0Á01), while Th2 cells were increased in the blood (P = 0Á01). The fall in circulating Th17 numbers, but none of the other changes, was related to clinical improvement, as change in Th17 blood levels correlated significantly to change in PASI ( Fig. S9d ; see Supporting Information).
Discussion
The present study of immunological changes associated with three effective treatments for psoriasis has, for the first time, revealed differential effects on CD4 + T-cell subsets and identified changes that correlate with clinical improvement. Patterns of change in the proportions of Teff and Treg subsets in the circulation and skin, including those that correlated with clinical improvement, depended on treatment type. The design of the study, comparing patients before and after treatment, allowed significant results to be obtained while applying stringent inclusion and exclusion criteria, and with patients allocated to different treatment arms on the basis of clinical decisions. The relatively short treatment interval focused on initial response rates, which are higher than those expected in longer studies that include relapses. Taken together, the results build on the understanding of psoriasis pathogenesis as an imbalance between CD4 + subsets by demonstrating that a range of current treatments target the imbalance in different ways and point to the possibility of improved therapies in future. NB-UVB enhanced the number of Tregs, reduced Th1 cells and had no significant effect on Th17 cells, while, by contrast, adalimumab lowered Th17 cells without noticeable effects on either Th1 or Treg cells. However, the topical Dovobet ointment was remarkable for its reciprocal effect in reducing effector (Th1 and Th17) subsets while increasing the proportion of Tregs. Moreover, the increase in UV-induced Tregs, and the Th17 falls caused by adalimumab and Dovobet, were correlated to improvements in PASI score. These results collectively emphasize the importance to therapeutic efficacy of . Note the significantly (*) higher proportions of Tregs in the skin and blood of healthy donors compared with patients (P < 0Á001 and P = 0Á001, respectively). The proportions of Th17 cells were significantly higher in the blood (P = 0Á004) and lesional skin (P < 0Á001) of patients than in the respective samples in the control. Also, skin Treg levels in healthy donors were significantly higher than nonlesional Treg levels of patients (P = 0Á007). PBMC, peripheral blood mononuclear cell.
restoring a Th17-Treg balance in psoriasis, and indicate that successful treatment can target either one or both sides of the imbalance.
Previous reports showed that psoriasis lesional Tregs are dysfunctional 5 or numerically deficient. 24 Our data showed significant differences in Treg numbers between patients and healthy controls, supporting previous findings 25, 26 and indicating that Tregs are important to maintain skin immune homeostasis in healthy skin. 27 The demonstration of Th17 cells enriched in psoriasis lesions compared with normal skin and healthy donor skin strongly supports the model of a Th17-Treg immune disturbance in psoriasis and reflects the frequent occurrence of skin-homing CD4 + T lymphocytes (CCR4 + CCR6 + ) in psoriasis plaques, providing more evidence that activation and recruitment of Th17 cells is pivotal for psoriasis pathogenesis. 4 Our findings suggest that lesional Tregs are numerous but are either dysfunctional or overwhelmed by chronic inflammatory microenvironments due to high numbers of Th17 cells and their cytokines. This in agreement with data shown by Keijsers et al. 28 and Rodriguez et al., 29 who reported increased percentages and absolute numbers of lesional FoxP3-expressing T cells, as well as production of IL-17 and interferon-c from these cells compared with nonlesional skin, supporting the concept of T-cell plasticity. 30 The reciprocal increase in Tregs and fall in Th17 cell numbers in response to Dovobet may be an example of a treatment driving subset plasticity in a beneficial direction. The striking increase in CD4 + CD25 + FoxP3 + CD127 lo Treg percentages, correlated to clinical response to NB-UVB, supports the notion that enhanced Tregs are key to improving psoriasis through restoration of immune tolerance, and the results also raise the possibility that a fall of Th1/Th2 ratio contributes to the beneficial effects of NB-UVB. Tregs has been the focus of a relatively recent study. 32 Furthermore, previous work in our laboratory highlighted a strongly correlated Treg response to serum vitamin D level following 2 weeks of NB-UVB therapy, 33 but other mediators such as nitric oxide may also be responsible for the induction by phototherapy of a CD4 + CD25 + FoxP3 À Treg population from CD4 + CD25 À FoxP3 À cells. 34 We showed for the first time in psoriasis that 6 weeks of treatment with adalimumab significantly reduced the percentages of lesional and peripheral blood Th17 cells, with a strong correlation to clinical response (r 2 = À0Á8, P = 0Á03). Other studies have revealed that TNF-a antagonists suppressed Th17 35 and Th22 signalling, 36 while others reported enhancement of Th1/Th17 cell activation in peripheral blood and inhibition of T-cell responses in the skin. 37 Although it has also been reported that anti-TNF-a agents can increase CD4 + CD25 + FoxP3 + cells in responding patients, 25, 26 we did not see such an effect. This may be because we used combined markers for Treg identification or due to the use of a different anti-TNF-a agent in the other studies.
There has been a growing interest in the role of vitamin D3 and analogues in the prevention of immune-mediated diseases. Some studies suggested that vitamin D deficiency is associated with autoimmune conditions 38 and active vitamin D analogues may prevent such disease by induction of Tregs. 33 Strikingly, Dovobet in our study showed significant systemic effects on Teffs and Tregs. Moreover, the fall in circulating Th17 cells was significantly correlated to clinical response (r 2 = À0Á7, P = 0Á04). This systemic effect of Dovobet may be mediated by the response to vitamin D by plasmacytoid dendritic cells. 39 Previous studies showed that vitamin D arrests the maturation of dendritic cells and increases the level of regulatory cytokines, IL-10 and transforming growth factor (TGF)-b in murine models of allergic asthma. 40 Thus, it is plausible that Dovobet improves psoriasis primarily by inducing Tregs, and that the effect on Th17 cells is secondary to the release of suppressive cytokines such as TGF-b and IL-10. However, the direct suppressive effects of betamethasone on Teff responses are also likely. In conclusion, this study identified immunological mechanisms of action of three commonly used psoriasis treatments. The results firstly support the model of psoriasis as an immune-mediated disease, in which there is a shift in the balance between Tregs that maintains self-tolerance towards a predominance of pathogenic Th17 cells. Furthermore, the work also has implications for optimizing existing, or developing new, treatment regimens. This study reveals that enhancing Treg proportions without necessarily compromising Th17 function is an effective treatment approach. The demonstration that existing treatments for psoriasis can exert selective effects on Treg and Teff subsets will also encourage a search for new strategies that restore tolerance without compromising protection against infectious disease. 
